CA3254011A1 - Inverse PPARG agonists and their uses - Google Patents
Inverse PPARG agonists and their usesInfo
- Publication number
- CA3254011A1 CA3254011A1 CA3254011A CA3254011A CA3254011A1 CA 3254011 A1 CA3254011 A1 CA 3254011A1 CA 3254011 A CA3254011 A CA 3254011A CA 3254011 A CA3254011 A CA 3254011A CA 3254011 A1 CA3254011 A1 CA 3254011A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- halo
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317740P | 2022-03-08 | 2022-03-08 | |
| US63/317,740 | 2022-03-08 | ||
| PCT/US2023/063643 WO2023172845A1 (en) | 2022-03-08 | 2023-03-03 | Pparg inverse agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3254011A1 true CA3254011A1 (en) | 2023-09-14 |
Family
ID=86006834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3254011A Pending CA3254011A1 (en) | 2022-03-08 | 2023-03-03 | Inverse PPARG agonists and their uses |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250186425A1 (https=) |
| EP (1) | EP4490147A1 (https=) |
| JP (1) | JP2025508542A (https=) |
| CN (1) | CN118984823A (https=) |
| AU (1) | AU2023231613A1 (https=) |
| CA (1) | CA3254011A1 (https=) |
| WO (1) | WO2023172845A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3254026A1 (en) * | 2022-03-08 | 2023-09-14 | Flare Therapeutics Inc. | Inverse PPARG agonists and their uses |
| WO2025098515A1 (en) * | 2023-11-10 | 2025-05-15 | Danatlas Pharmaceuticals Co., Ltd. | Heterocyclic derivatives, compositions and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001083427A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | PPARη MODULATORS |
| AU2006223000B2 (en) * | 2005-03-14 | 2011-06-30 | Center For Molecular Medicine And Immunology | Methods of treating cancer using PPAR-gamma antagonists |
| CZ300589B6 (cs) * | 2006-09-04 | 2009-06-24 | Univerzita Palackého | Deriváty 2-fenyl-3-hydroxychinolin-4(1H)-onu a zpusob jejich prípravy a použití |
| CN105982884B (zh) * | 2015-02-25 | 2019-05-24 | 上海中医药大学 | 一种补骨脂二氢黄酮甲醚及其类似物的用途 |
| CN107661333B (zh) * | 2016-07-27 | 2020-12-29 | 清华大学 | 化合物在治疗肺癌中的应用 |
| CN107522657B (zh) * | 2017-09-28 | 2020-06-26 | 上海中医药大学 | 一种具有ppar多重激动活性的化合物及其制备方法和应用 |
| EP3498694A1 (en) * | 2017-12-12 | 2019-06-19 | Medibiofarma, S.L. | New benzamide derivatives as ppar-gamma modulators |
| CN117616012A (zh) * | 2021-03-02 | 2024-02-27 | 弗拉雷治疗公司 | Pparg反向激动剂及其用途 |
| CA3227603A1 (en) * | 2021-08-05 | 2023-02-09 | Jonathan E. Wilson | Pparg inverse agonists and uses thereof |
-
2023
- 2023-03-03 EP EP23716983.4A patent/EP4490147A1/en active Pending
- 2023-03-03 WO PCT/US2023/063643 patent/WO2023172845A1/en not_active Ceased
- 2023-03-03 JP JP2024552725A patent/JP2025508542A/ja active Pending
- 2023-03-03 CN CN202380033175.XA patent/CN118984823A/zh active Pending
- 2023-03-03 AU AU2023231613A patent/AU2023231613A1/en active Pending
- 2023-03-03 CA CA3254011A patent/CA3254011A1/en active Pending
- 2023-03-03 US US18/844,419 patent/US20250186425A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250186425A1 (en) | 2025-06-12 |
| EP4490147A1 (en) | 2025-01-15 |
| CN118984823A (zh) | 2024-11-19 |
| JP2025508542A (ja) | 2025-03-26 |
| WO2023172845A1 (en) | 2023-09-14 |
| AU2023231613A1 (en) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7853310B2 (ja) | Ｐｐａｒｇ逆アゴニストおよびその使用 | |
| US11820747B2 (en) | PPARG inverse agonists and uses thereof | |
| EP4380928B1 (en) | Pparg inverse agonists and uses thereof | |
| CA2923269C (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
| CN109071498A (zh) | 激酶抑制剂及其制备方法和用途 | |
| CA3254011A1 (en) | Inverse PPARG agonists and their uses | |
| EP4489863A1 (en) | Pparg inverse agonists and uses thereof | |
| HK40118248B (en) | Pparg inverse agonists and uses thereof | |
| HK40118248A (en) | Pparg inverse agonists and uses thereof | |
| EA051641B1 (ru) | Обратные агонисты pparg и их применения | |
| WO2024138211A1 (en) | Pparg inverse agonists and uses thereof | |
| US20240239760A1 (en) | Pparg inverse agonists and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240906 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250123 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250123 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250123 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250131 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250303 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250303 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260227 |